LifeStance Health Group, Inc. (LFST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 600M 1.2B 1.8B Q3 '21: 595.6M Q4 '21: 667.5M Q1 '22: 727.5M Q2 '22: 776.5M Q3 '22: 820.2M Q4 '22: 859.5M Q1 '23: 909M Q2 '23: 959.1M Q3 '23: 1B Q4 '23: 1.1B Q1 '24: 1.1B Q2 '24: 1.2B Q3 '24: 1.2B Q4 '24: 1.3B Q1 '25: 1.3B Q2 '25: 1.3B Q3 '25: 1.4B Q4 '25: 1.4B Q1 '26: 1.5B Q2 '26: 1.6B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '21: -168.6M Q4 '21: -286.4M Q1 '22: -350.3M Q2 '22: -363.8M Q3 '22: -277.9M Q4 '22: -210.2M Q1 '23: -179.4M Q2 '23: -167.4M Q3 '23: -202.9M Q4 '23: -189.1M Q1 '24: -171.8M Q2 '24: -139.3M Q3 '24: -64.9M Q4 '24: -31.6M Q1 '25: -13.2M Q2 '25: -240K Q3 '25: 7.1M Q4 '25: 24.1M Q1 '26: 44.8M Q2 '26: 78.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '21: -204.7M Q4 '21: -307.2M Q1 '22: -360.8M Q2 '22: -359.5M Q3 '22: -276.9M Q4 '22: -215.6M Q1 '23: -187.5M Q2 '23: -164.2M Q3 '23: -188M Q4 '23: -186.3M Q1 '24: -173.1M Q2 '24: -150.9M Q3 '24: -88.6M Q4 '24: -50.8M Q1 '25: -29M Q2 '25: -9.5M Q3 '25: -9.1M Q4 '25: 9.7M Q1 '26: 23.2M Q2 '26: 50.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-80M 0 80M 160M 240M Q3 '21: -17.1M Q4 '21: 9.4M Q1 '22: 2.8M Q2 '22: 27.6M Q3 '22: 47.5M Q4 '22: 52.8M Q1 '23: 41.6M Q2 '23: 33.3M Q3 '23: 2.2M Q4 '23: -16.9M Q1 '24: -30.8M Q2 '24: 13.7M Q3 '24: 61.7M Q4 '24: 107.3M Q1 '25: 126M Q2 '25: 146.3M Q3 '25: 150.9M Q4 '25: 146.2M Q1 '26: 182.4M Q2 '26: 217.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-120M -60M 0 60M 120M 180M Q3 '21: -83.5M Q4 '21: -85.1M Q1 '22: -108.5M Q2 '22: -88.9M Q3 '22: -60M Q4 '22: -26.5M Q1 '23: -17.5M Q2 '23: -11.5M Q3 '23: -37.3M Q4 '23: -57.4M Q1 '24: -68.7M Q2 '24: -17.8M Q3 '24: 35.1M Q4 '24: 85.7M Q1 '25: 102.4M Q2 '25: 120.1M Q3 '25: 119.4M Q4 '25: 110M Q1 '26: 142.6M Q2 '26: 173.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q2 '21: 313.5K Q3 '21: 343.4K Q1 '22: 350.8K Q2 '22: 353.7K Q3 '22: 357.5K Q1 '23: 360.9M Q2 '23: 363.2M Q3 '23: 372.5M Q1 '24: 376.3M Q2 '24: 379.4M Q3 '24: 380.4M Q1 '25: 390.7M Q2 '25: 386.7M Q3 '25: 388.9M Q1 '26: 395.1M Q2 '26: 387.3M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.